| HOME >> MEDICINE >> TECHNOLOGY |
57.5%55.9%Amortization of acquired intangible assets
(1,510)(1,144)Share-based compensation
(99)(178)GAAP gross profit
82,25099,719GAAP gross margin
56.4%55.1%Non-GAAP selling expenses(22,377)(31,966)Non-GAAP as % of total revenues
15.3%17.7%Amortization of acquired intangible assets
(622)(623)Share-based compensation
(665)(1,083)GAAP selling expenses
(23,664)(33,672)GAAP as % of total revenues
16.2%18.6%Non-GAAP general and administrative expenses(11,768)(13,928)Non-GAAP as % of total revenues
8.1%7.7%Share-based compensation
(478)(499)GAAP general and administrative expenses
(12,246)(14,427)GAAP as % of total revenues
8.4%8.0%Non-GAAP research and development expenses(13,771)(17,569)Non-GAAP as % of total revenues
9.4%9.7%Share-based compensation
(664)(1,019)GAAP research and development expenses
(14,435)(18,588)GAAP as % of total revenues
9.9%10.3%Exhibit 5MINDRAY MEDICAL INTERNATIONAL LIMITEDRECONCILIATION OF GAAP NET INCOME TO EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION AND AMORTIZATION(Dollars in thousands)Three months ended March 31, 2010 2011 US$US$(unaudited)(unaudited)GAAP net income
36,19737,710Interest income
(2,134)(3,509)Interest expense
1,406220Income tax benefits
(3,447)(963)Earnings before interest and taxes ("EBIT")
32,02233,458Depreciation
4,5335,048Amortization
2,2502,323Earnings before interest, taxes, depreciation, and amortization ("EBITDA")
38,80540,829
'/>"/>
| SOURCE Mindray Medical International Limited Copyright©2010 PR Newswire. All rights reserved |